Free Trial Information
BioCentury | Sep 12, 2019
Distillery Therapeutics

Inhibition of G9A and DNMT methyltransferases in bladder cancer

DISEASE CATEGORY: Cancer INDICATION: Bladder cancer Dual inhibition of G9A and DNMT methyltransferases, in combination with cisplatin and anti-programmed cell death 1 ligand 1 (PD-L1), could help to treat bladder cancer. A tool compound that...
Read More
BioCentury | Apr 19, 2019
Company News

BioSense gets Asia rights to Rexahn's pancreatic cancer therapy

BioSense gained exclusive rights to develop and commercialize Rexahn's RX-3117 to treat and prevent pancreatic cancer in Singapore, China, Hong Kong, Macau and Taiwan. Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) will receive $3 million up front and...
Read More
BioCentury | Aug 3, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
Read More
BioCentury | Jul 31, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
Read More
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
Read More
BioCentury | Oct 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample and mouse studies suggest inhibiting DNMT1 could help treat gastric cancer. In patients, high levels of DNMT1 in tumor samples were associated with disease progression and poor overall survival. In...
Read More
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...myelogenous leukemia (AML); colorectal cancer Eliminating proleukemia cells expressing DNMT3A could help treat AML; a DNMT3A...
Read More
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML); B cell lymphoma Cell culture and mouse studies identified an aminoquinoline-based dual DNMT1 / EHMT2 inhibitor that could help treat ALL, AML and diffuse large B...
Read More
BioCentury | May 16, 2017
Distillery Therapeutics

Cancer

...INDICATION: Colorectal cancer In vitro and cell culture studies identified a quinolone-quinazoline conjugate-based DNMT3A inhibitor that...
...analogs in vitro yielded a compound that inhibited the activity of the catalytic domain of DNMT3A...
...include testing the compound in xenograft models of colorectal cancer. TARGET/MARKER/PATHWAY: DNA (cytosine-5-)-methyltransferase 3 α (DNMT3A...
Read More
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
Read More
Items per page:
1 - 10 of 55